These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 34496885

  • 1. An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks.
    Ramírez-Moya J, Miliotis C, Baker AR, Gregory RI, Slack FJ, Santisteban P.
    Mol Cancer; 2021 Sep 08; 20(1):115. PubMed ID: 34496885
    [Abstract] [Full Text] [Related]

  • 2. ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity.
    Ramírez-Moya J, Baker AR, Slack FJ, Santisteban P.
    Oncogene; 2020 Apr 08; 39(18):3738-3753. PubMed ID: 32157211
    [Abstract] [Full Text] [Related]

  • 3. CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients.
    Dong X, Chen G, Cai Z, Li Z, Qiu L, Xu H, Yuan Y, Liu XL, Liu J.
    Cell Physiol Biochem; 2018 Apr 08; 47(6):2602-2612. PubMed ID: 29996118
    [Abstract] [Full Text] [Related]

  • 4. ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner.
    Zhu T, Li Q, Zhang Z, Shi J, Li Y, Zhang F, Li L, Song X, Shen J, Jia R.
    BMC Biol; 2024 Jun 05; 22(1):132. PubMed ID: 38835016
    [Abstract] [Full Text] [Related]

  • 5. Adenosine Deaminases Acting on RNA Downregulate the Expression of Constitutive Androstane Receptor in the Human Liver-Derived Cells by Attenuating Splicing.
    Nakano M, Fukami T, Nakajima M.
    J Pharmacol Exp Ther; 2019 Sep 05; 370(3):408-415. PubMed ID: 31270214
    [Abstract] [Full Text] [Related]

  • 6. Combinatory RNA-Sequencing Analyses Reveal a Dual Mode of Gene Regulation by ADAR1 in Gastric Cancer.
    Cho CJ, Jung J, Jiang L, Lee EJ, Kim DS, Kim BS, Kim HS, Jung HY, Song HJ, Hwang SW, Park Y, Jung MK, Pack CG, Myung SJ, Chang S.
    Dig Dis Sci; 2018 Jul 05; 63(7):1835-1850. PubMed ID: 29691780
    [Abstract] [Full Text] [Related]

  • 7. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.
    Qin YR, Qiao JJ, Chan TH, Zhu YH, Li FF, Liu H, Fei J, Li Y, Guan XY, Chen L.
    Cancer Res; 2014 Feb 01; 74(3):840-51. PubMed ID: 24302582
    [Abstract] [Full Text] [Related]

  • 8. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.
    Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, Liu M, Song Y, Chow RK, Ng VH, Yuan YF, Tenen DG, Guan XY, Chen L.
    Gut; 2014 May 01; 63(5):832-43. PubMed ID: 23766440
    [Abstract] [Full Text] [Related]

  • 9. ADARs and editing: The role of A-to-I RNA modification in cancer progression.
    Fritzell K, Xu LD, Lagergren J, Öhman M.
    Semin Cell Dev Biol; 2018 Jul 01; 79():123-130. PubMed ID: 29146145
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nucleoside analog studies indicate mechanistic differences between RNA-editing adenosine deaminases.
    Mizrahi RA, Phelps KJ, Ching AY, Beal PA.
    Nucleic Acids Res; 2012 Oct 01; 40(19):9825-35. PubMed ID: 22885375
    [Abstract] [Full Text] [Related]

  • 13. ADAR1-mediated RNA-editing of 3'UTRs in breast cancer.
    Sagredo EA, Blanco A, Sagredo AI, Pérez P, Sepúlveda-Hermosilla G, Morales F, Müller B, Verdugo R, Marcelain K, Harismendy O, Armisén R.
    Biol Res; 2018 Oct 05; 51(1):36. PubMed ID: 30290838
    [Abstract] [Full Text] [Related]

  • 14. Transcriptome Profiling of ADAR1 Targets in Triple-Negative Breast Cancer Cells Reveals Mechanisms for Regulating Growth and Invasion.
    Baker AR, Miliotis C, Ramírez-Moya J, Marc T, Vlachos IS, Santisteban P, Slack FJ.
    Mol Cancer Res; 2022 Jun 03; 20(6):960-971. PubMed ID: 35247916
    [Abstract] [Full Text] [Related]

  • 15. Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer.
    Okugawa Y, Toiyama Y, Shigeyasu K, Yamamoto A, Shigemori T, Yin C, Ichikawa T, Yasuda H, Fujikawa H, Yoshiyama S, Hiro J, Ohi M, Araki T, Kusunoki M, Goel A.
    J Transl Med; 2018 Dec 18; 16(1):366. PubMed ID: 30563560
    [Abstract] [Full Text] [Related]

  • 16. ADAR1 and its implications in cancer development and treatment.
    Baker AR, Slack FJ.
    Trends Genet; 2022 Aug 18; 38(8):821-830. PubMed ID: 35459560
    [Abstract] [Full Text] [Related]

  • 17. RNA-editing enzymes ADAR1 and ADAR2 coordinately regulate the editing and expression of Ctn RNA.
    Anantharaman A, Gholamalamdari O, Khan A, Yoon JH, Jantsch MF, Hartner JC, Gorospe M, Prasanth SG, Prasanth KV.
    FEBS Lett; 2017 Sep 18; 591(18):2890-2904. PubMed ID: 28833069
    [Abstract] [Full Text] [Related]

  • 18. AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer.
    Shigeyasu K, Okugawa Y, Toden S, Miyoshi J, Toiyama Y, Nagasaka T, Takahashi N, Kusunoki M, Takayama T, Yamada Y, Fujiwara T, Chen L, Goel A.
    JCI Insight; 2018 Jun 21; 3(12):. PubMed ID: 29925690
    [Abstract] [Full Text] [Related]

  • 19. The majority of A-to-I RNA editing is not required for mammalian homeostasis.
    Chalk AM, Taylor S, Heraud-Farlow JE, Walkley CR.
    Genome Biol; 2019 Dec 09; 20(1):268. PubMed ID: 31815657
    [Abstract] [Full Text] [Related]

  • 20. An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1).
    George CX, John L, Samuel CE.
    J Interferon Cytokine Res; 2014 Jun 09; 34(6):437-46. PubMed ID: 24905200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.